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Background: The chitinase-like protein, Chi3L1, is associated with increased ﬁbrotic activity as well as inﬂamma-
tory processes. The capacity of skin cells from systemic sclerosis (SSc) patients to produce Chi3L1, and the
stimulation of its synthesis by cytokines or growth factors known to be associated with SSc, was investigated.
Methods: Cells were isolated from forearm and/or abdomen skin biopsies taken from SSc patients and normal in-
dividuals and stimulated with cytokines and growth factors to assess Chi3L1 expression. Chi3L1-expressing cells
were characterized by immunohistochemical staining.
Results: Chi3L1was not secreted by skin cells from normal individuals norwas its synthesis induced by any of the
cytokines or growth factors investigated. In contrast, Chi3L1 secretion was induced by OSM or IL-1 in cells from
all forearm biopsies of SSc patients, and endogenous secretion in the absence of cytokineswas detected in several
specimens. Patientswith Chi3L1-producing cells at both the arm and abdomen had a disease duration of less than
3 years. Endogenous Chi3L1 production was not a property of the major ﬁbroblast population nor of
myoﬁbroblasts, but rather was related to the presence of stem-like cells not present in normal skin. Other
cells, however, contributed to the upregulation of Chi3L1 by OSM.
Conclusions: The emergence of cells primed to respond to OSM with increased Chi3L1 production appears to be
associated with pathological processes active in SSc.
General signiﬁcance: The presence of progenitor cells expressing the chilectin Chi3L1 in SSc skin appears to play a
role in the initiation of the disease process.© 2013 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Systemic sclerosis (scleroderma, SSc) is a complex autoimmune
disease with a highly variable array of clinical features, the most charac-
teristic being an overproduction and excessive deposition of collagen in
the skin and internal organs, with a progressive course and often fatal
outcome. It is relatively rare, affecting between 50,000 and 100,000
North Americans, and up to 250,000 Europeans [1,2]. Although less com-
mon than other rheumatic diseases, it has one of the highest mortality
rates [3].
Disturbances of both the immune and vascular systems are thought
to contribute to the development of SSc. Endothelial alterations often4′,6-diamidino-2-phenylindole;
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. This is an open access article underoccur early in the disease, followed by vascular damage that leads to a
cascade of stimulatory changes culminating in tissue ﬁbrosis [4]. This
process involves T lymphocytes [5], monocytes, macrophages [6]
and mast cells [7] as well as ﬁbroblasts [8]. The activated cells secrete
a variety of products, including growth factors, cytokines and their
antagonists [9]. These substances cause inﬂammation and increased
deposition of extracellular matrix (ECM) components, leading to
progressive andwidespread tissue ﬁbrosis. The heterogeneity of various
forms of SSc and the difﬁculty in discriminating between disease
activity (aspects of the disease that vary over time and are potentially
reversible spontaneously or with drug treatment) and disease damage
(irreversible tissue injury that results from the disease) [10] complicate
studies of SSc. At present there are no validated biomarkers which
can be used to monitor disease progression. There is an extensive
literature, however, investigating the relationship between many of
the cytokines and effector molecules implicated in the various patho-
logical processes associated with the development and progression of
SSc [11–15].
The chitinase-like protein, Chi3L1 (YKL40, HCgp39), has been shown
to be associated with increased ﬁbrotic activity as well as inﬂammatory
processes. Chi3L1 is upregulated inmanypathological conditions [16–23].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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shorter recurrence-free interval and low overall survival [16,17] in pa-
tients with a broad range of cancers, including breast [16] and colorectal
cancers [17]. Patients with diseases characterized by inﬂammation and
tissue ﬁbrosis, including rheumatoid arthritis [18], osteoarthritis [19],
pneumonia [20], liver cirrhosis [21] and systemic sclerosis (SSc) [22–24]
are also reported to have elevated serum Chi3L1 levels. Chi3L1 belongs
to the family of mammalian chitinase-like proteins, which share primary
sequence homology and three-dimensional structure with the family 18
glycohydrolases [25] but lack chitinolytic activity. The lack of catalytic
activity is due to two amino acid substitutions in the active site region
of the protein, the most critical one being substitution of the catalytic
glutamate residue with leucine [26].
Chi3L1 is produced bymacrophages, synovial cells and chondrocytes
from arthritic joints [27], and neutrophils [28]. It has been shown to act
synergistically with insulin-like growth factor (IGF-1) in ﬁbroblasts to
stimulate cell growth [29]. The protein also has mitogenic effects on
chondrocytes and synovial cells and promotes proteoglycan synthesis
in these cells [30]. Furthermore, Chi3L1 has been shown to be a
migration and adhesion factor for vascular smooth muscle cells, which
suggests a role in angiogenesis [31]. Previous work has demonstrated
that Chi3L1 can modulate the response of connective tissue cells to
inﬂammatory cytokines, such as IL-1 or TNF-α [32]. Chi3L1−/−micedis-
play an exaggerated inﬂammatory response in a lung injurymodel [33],
supporting this observation. The detailed molecular mechanisms by
which Chi3L1 exerts its biological effects are not known.
In SSc, dermal ﬁbroblasts are one of the main effector cells involved
in the development of ﬁbrotic lesions, and their biological activity is
regulated by a variety of inﬂammatory cytokines and growth factors.
Chi3L1 had been implicated in other pathologies leading to excessive
ﬁbrosis [34], and thus its production might be upregulated in affected
tissues in patientswith SSc. The goals of the presentworkwere to inves-
tigate the capacity of skin cells fromSSc patients and healthy individuals
to synthesize Chi3L1 and to assess the regulation of this process by
growth factors and cytokines shown to be associated with this disease.
2. Materials and methods
2.1. Patients, controls, and skin biopsies
Full-thickness biopsieswere obtained by an experienced rheumatol-
ogist (MB) from the skin of the distal forearm and abdomen of 41 SSc
patients recruited from the Canadian Scleroderma Research Group
(CSRG) Registry. Similar skin biopsies were also obtained from 10
healthy control individuals. To be eligible for the Registry, patients
must have a diagnosis of SSc made by the referring rheumatologist, be
age≥18 years, and be ﬂuent in English or French. Registry patients un-
dergo an extensive clinical history, physical evaluation, and laboratory
investigations, and complete a series of self-report questionnaires.
Clinical sclerodermatous involvement of skin from biopsy sites was
determined by an experienced rheumatologist (MB). Patients and indi-
viduals for control biopsies providedwritten informed consent, and the
sample collection and analysis protocols were approved by the McGill
University Institutional Review Board. Patients were classiﬁed as having
limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc) accord-
ing to the classiﬁcation by LeRoy et al. [35]. Disease duration was calcu-
lated from the date of appearance of the ﬁrst non-Raynaud's symptom
of SSc. This is based on both cutaneous and systemic symptoms,
including respiratory symptoms, ﬁnger ulcers, inﬂammatory arthritis, tel-
angiectasia, skin tightening anywhere, fatigue, puffy extremities (hands
or feet), weight loss, heartburn or dysphagia and erectile dysfunction.
2.2. SSc clinical outcomes
Using standardizeddeﬁnitions, the recruiting rheumatologist (MB) re-
ported whether or not the patients had active or healed digital ulcers,interstitial lung disease and pulmonary hypertension. Disease activity
was measured using the Valentini Scleroderma Disease Activity Index
(SDAI) [36,37], consisting of 10 variables with weights ranging from 0.5
to 2.0 and resulting in a total score ranging from 0 to 10. Variables being
measured with the SDAI include modiﬁed Rodnan skin score (N14),
scleredema, change in skin symptoms in the last month, digital necrosis,
change in vascular symptoms in the last month, arthritis, lung diffusion
capacity b80% predicted, change in cardiopulmonary symptoms, erythro-
cyte sedimentation rate N30 mm/h and hypocomplementemia [36,37].
Disease severity was measured using physician global assessments of
disease severity (scales ranging from 0 to 10) [38]. Predictors of disease
severity have been shown to include skin involvement, severity of
Raynaud's phenomenon, shortness of breath, gastrointestinal symptoms
andpain, number ofﬁngertip ulcers, tender and swollen joints, creatinine,
and fatigue [38].
2.3. Cell isolation and culture
Full thickness skin biopsieswere collected at bedside and placed into
Falcon tubes containing 10 ml Dulbecco's modiﬁed Eagle medium
(DMEM) (Gibco BRL, Grand Island, NY, USA). To separate epidermis
from dermis 0.5% dispase (Invitrogen, Burlington, Canada) was added
and the skin biopsies were incubated at 37 °C, in 5% CO2 for 2 h. Cells
were isolated by incubation of dermal samples overnight at 37 °C
under gentle mixing in a solution of 0.2% collagenase H (Sigma, St
Louis, MO, USA) in DMEM, and 100 U/ml penicillin, and 100 μg/ml
streptomycin (Schering Inc., Pointe Claire, Canada). DMEM with 5%
fetal calf serum (FCS) was added to neutralize the activity of collage-
nase. The mixture was centrifuged for 5 min at 500 g. The cell pellet
was resuspended with 1 ml DMEM, and cell viability was assessed by
Trypan Blue exclusion. Cells were then plated in T-75 culture ﬂasks
(Becton Dickinson, Franklin Lakes, NJ, USA) and maintained in 12 ml
DMEM supplemented with 5% FCS and antibiotics at 37 °C in a 5%
CO2/95% air atmosphere. Culture media were changed every 3 days
until cells reached 90% conﬂuency. At this point the cells were
sub-cultured at a ratio of 1:3 by trypsinization. It is expected that
these cell preparations would be enriched in ﬁbroblasts, but they
could also contain any other cell types capable of adherence to tissue
culture plastic.
2.4. Stimulation of skin cells by cytokines and growth factors
Skin cellswere plated in T-25 cultureﬂasks at 4 × 105 cells/ﬂask and
were cultured to near conﬂuence in DMEM supplemented with 5% FCS
and antibiotics, followed by 24 h of incubation in serum-free conditions
before stimulation with growth factors or cytokines. Cells were either
left untreated or treated with 10 ng/ml recombinant interleukin-1β
(IL-1β), interleukin-6 (IL-6), interleukin-17 (IL-17), oncostatin M
(OSM), transforming growth factor-β (TGFβ) or platelet-derived
growth factor (PDGF) (R&D Systems, Minneapolis, MN, USA) in 3.5 ml
DMEM for 48 h. Conditioned media were collected and secreted
proteins were analyzed by SDS-PAGE followed by western blotting.
2.5. Soybean trypsin inhibitor (SBTI) biotinylation
Soybean trypsin inhibitor (SBTI,MW24 kDa)was used as a control for
the efﬁciency of acetone precipitation of cell culture media prior to
SDS-PAGE. The protein was biotinylated with sulfosuccinimidyl-6-
(biotin-amido) hexanoate (Sulfo-NHS-LC-Biotin; Pierce, Rockford, IL,
USA), following the manufacturer's instructions, to allow detection in
western blots with the streptavidin–biotin system used for detection of
Chi3L1. Excess Sulfo-NHS-LC-Biotin was removed by overnight dialysis
(Nominal MWCO: 12,000–14,000; Fisher Scientiﬁc, Ottawa, Canada)
into 10 l of 100 mM Tris, pH 7.6 at 4 °C. Ten ng biotinylated SBTI was
sufﬁcient for use as a control for detection by western blotting.
Table 1
Summary features of patients studied (n = 41).
Variables Value % or range
Age (years) [mean] 57 39–77
Female (n) 35 85%
Disease duration (years) [mean] 10.2 1.3–48.9
Type of systemic sclerosis
Limited (n) 23 56%
Early limited (n) 9 22%
Diffuse (n) 18 44%
Early diffuse (n) 2 5%
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(SDS-PAGE) and western blotting
Cell conditioned media (300 μl) supplemented with 10 ng biotinyl-
ated SBTI were precipitated with 600 μl cold acetone overnight at
−20 °C. The pellet was washed twice with 1 ml cold acetone, dried
and resuspended in 24 μl H2O. Sample buffer containing reducing
agent was added to the reconstituted pellet sample, and incubated at
70 °C for 10 min. Proteins were then separated on NuPAGE Bis–Tris
4–12%, 1 mm gels, at 180 V for 1 h. The proteins were then transferred
to nitrocellulose membrane (0.45 μm) (Bio-Rad, Hercules, CA, USA) at
30 V for 90 min. After transfer, membranes were blocked for 1 h with
5% dried skimmed milk in Tris-buffered saline–Tween 20 (TBS-T). The
membranes were probed overnight at 4 °C with primary antibody:
rabbit anti-human Chi3L1 polyclonal antibody raised against the
C-terminal peptide CGTNAIFDALAAT conjugated to ovalbumin. The
membraneswerewashed four times,with TBS-T followedby incubation
with donkey anti-rabbit, biotinylated species-speciﬁc antibody (1:5000
dilution; GE Health Care, Little Chalfont, UK) for 60 min. The
membranes were again washed with TBS-T, then incubated with a
streptavidin–biotinylated horseradish peroxidase complex (1:750
dilution; GE Health Care, Little Chalfont, UK) for 60 min. After wash-
ing the membranes with TBS-T, the protein bands were visualized
using ECL reagents (GE Health Care, Pittsburgh, PA, USA). Puriﬁed
Chi3L1, used as a standard, was isolated from human chondrocyte
cultures [39].
2.7. Immunoﬂuorescence analysis of cell phenotype
Fibroblasts were subcultured in 6-well plates on microscope cover-
slips at a density of 2 × 105 cells per well. Cells were cultured to near
conﬂuence in DMEM supplementedwith 5% FCS and antibiotics, follow-
ed by 24 h in serum-free conditions before stimulation with growth
factors or cytokines. Cells were either left untreated or treated with
10 ng/ml OSM or TGFβ in 3.5 ml DMEM for 48 h, then rinsed with
phosphate-buffered saline (PBS) and ﬁxed with 4% paraformaldehyde
at room temperature for 15 min. After three PBS washes, the cells
were permeabilized with PBT (PBS plus 1% Triton X-100) for 30 min
prior to blocking with 0.1% bovine serum albumin (BSA), 5% goat
serum in PBS for 1 h at room temperature. Primary antibodies diluted
in blocking solution were then added and incubated overnight at 4 °C.
Primary antibodies: rabbit anti-human Chi3L1 polyclonal antibody at
1:200 dilution, mouse anti-human smooth muscle actin (αSMA)
monoclonal antibody at 1:1000 dilution (Invitrogen, Camarillo, CA,
USA), mouse anti-human nestin monoclonal antibody at 1:200 dilution,
mouse anti-human CD73 monoclonal antibody at 1:200 dilution, mouse
anti-human STRO-1 monoclonal antibody at 1:200 dilution, mouse anti-
human TIE-2 monoclonal antibody at 1:200 dilution, mouse anti-human
CD45 monoclonal antibody at 1:200 dilution, mouse anti-human CD34
monoclonal antibody at 1:200 dilution (Abcam, Cambridge, MA, USA),
mouse anti-human LSP-1 antibody at 1:200 dilution (Abnova Coopera-
tion, Taipei, Taiwan), and rabbit NG2 chondroitin sulfate proteoglycan
polyclonal antibody at 1:200 dilution (Millipore, Temecula, CA, USA).
Mouse IgG1 at 1:200 dilution (Abcam, Cambridge, MA, USA) or normal
rabbit IgG at 10 μg/ml were used as negative controls. The cells were
thenwashed three times in PBS before incubation for 1 h at room temper-
aturewith secondary antibodies: goat anti-rabbit Alexa 488 andgoat anti-
mouse Alexa 594. Following three PBS washes, the coverslips were
mounted inverted on glass slides with Vectashield mounting medium
with DAPI (Vector Laboratories, Burlingame, CA, USA) and sealed with
nail polish. The labeled cells were evaluated by ﬂuorescence microscopy,
and quantiﬁed by cell counting using 20 representative ﬁelds.
2.8. Statistical analysis
Data were analyzed using the Mann–Whitney U test.3. Results
3.1. Patient characteristics
Sixty-one skin cell cultures from 41 SSc patients (35 women, 6men;
mean age 57 years, range 39–77 years) were used in this work. The
mean disease duration was 10.2 years, ranging from 1.3 to 48.9 years.
The features of the patients studied are summarized in Table 1. For 20
patients, skin cells derived from biopsies taken from both the arm and
abdomen were available and analyzed with respect to Chi3L1 produc-
tion, allowing comparison of the behavior of cells from the same
patient, isolated from these two different sites (Table 2); for 9 patients,
only cells derived from the arm were available (Table 3) and for 12 pa-
tients, only cells derived from the abdomen were available (Table 3).
Modiﬁed Rodnan scores and skin scores from the sites where the biop-
sies were taken are indicated in Table 4. The control group (Table 5)
consisted of 9 females and 1 male, with a mean age of 53 years, range
44–61 years. Biopsies from both the arm and abdomen were taken
from 5 members of this group, the remainder provided arm biopsies
only.
3.2. Chi3L1 secretion by SSc cells
Chi3L1 production and its regulation by cytokines or growth factors
thought to be associated with SSc disease pathology were analyzed in
15 cell lines from the skin of 10 control individuals and 61 cell lines
from skin biopsies of 41 SSc patients. Cells were stimulated with IL-1β,
IL-6, IL-17, OSM, TGFβ or PDGF and Chi3L1 levels in the culture media
were analyzed by SDS-PAGE and western blotting. Chi3L1 secretion
was not detectable in any of the 15 unstimulated healthy control skin
cell lines analyzed, nor was it induced by any of the cytokines or growth
factors tested in this study (Fig. 1A). In contrast, endogenous Chi3L1
secretion was observed in 22 of the 61 SSc skin cell lines analyzed. The
level of secreted Chi3L1 was increased when these 22 SSc skin cell
lines were stimulated with IL-1β or OSM, with OSM having the more
prominent effect (Fig. 1B), while IL-6, IL-17, TGFβ and PDGF had no
effect. All cell preparations from SSc patients which produced Chi3L1
always responded to both IL-1β and OSM, and there was no synergism
between these cytokines. For those 39 SSc cell lines which did not show
endogenous Chi3L1 secretion, the protein was detected in 19 of the cell
lines after stimulationwith IL-1 or OSM.None of the other cytokines and
growth factors tested affected Chi3L1 secretion. Since the greatest
stimulation of Chi3L1 production was induced by OSM, this cytokine
was used in further studies.
SSc skin ﬁbroblasts have been reported to possess unstable pheno-
types with respect to ECM production [40]. This could be due to the
sampling site of the biopsy or to variations in the stability of the ﬁbro-
blast phenotype from different individuals. To ascertain that differences
in the secretion of Chi3L1 between the different SSc cell lines were not
due to instability of the ﬁbroblast phenotype, 3 cell lines that endoge-
nously secretedChi3L1were continued in culture frompassage 7 topas-
sage 10. Endogenous Chi3L1 secretion was maintained and remained
inducible by OSM at all passages though absolute levels did vary
(Fig. 2). Moreover, cell lines that did not express Chi3L1 never attained
Table 2
Chi3L1 secretion pattern of skin cells isolated from paired biopsy sites of SSc patients.
Patient characteristics Biopsy site
Patient ID Gender Age (years) Disease duration
(years)
SSc subtype Forearm Abdomen
Clinically
involved
Endogenous
Chi3L1 secretion
Induction
by OSM
Clinically
involved
Endogenous
Chi3L1 secretion
Induction
by OSM
1 Female 53 2.5 Limited No + + No + +
2 Male 69 1.7 Limited No + + No + +
3 Female 58 1.5 Diffuse Yes + + Yes + +
4 Female 52 1.3 Limited No + + No + +
S Female 55 2.0 Limited No + + No + +
6 Female 63 1.3 Diffuse No + + No + +
7 Female 60 23.5 Limited No + + No − −
8 Female 46 15.6 Diffuse Yes + + No − −
9 Female 78 11.0 Diffuse No + + No − −
10 Male 63 8.8 Diffuse No + + No − −
11 Female 49 2.9 Limited No + + No − −
12 Female 64 14.8 Limited No − + No − +
13 Female 66 5.6 Limited No − + No − +
14 Female 51 13.6 Diffuse Yes − + Yes − +
15 Female 70 28.5 Limited Yes − + Yes − +
16 Female 61 10.3 Limited No − + No − −
17 Female 69 48.9 Limited No − + No − −
18 Male 77 14.5 Limited No − + No − −
19 Female 46 6.9 Diffuse Yes − + No − −
20 Female 55 12.6 Diffuse Yes + Yes − −
Cells were isolated from skin biopsies as indicated and cultured in the absence or presence of OSM. Chi3L1 secretionwas determined bywestern blotting. Chi3L1 secretionwas induced by
OSM in cells isolated from forearm biopsies in all 20 patients. + indicates detection of endogenous Chi3L1 or an increase over the endogenous level induced by OSM, but does not reﬂect
absolute levels.
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that Chi3L1 is not secreted by normal skin cells nor is its production
induced by inﬂammatory or ﬁbrogenic cytokines in these cells. In
contrast it is produced in an inducible and stable fashion by a majority
of SSc skin cell preparations and is likely to reﬂect an in vivo situation.
Three different patterns of Chi3L1 secretion and regulationwere ob-
served in the SSc skin cell preparations used for this study (Fig. 3).
Group 1 represents the skin cells that constitutively secreted Chi3L1
and this process was stimulated by OSM. Group 2 represents the skin
cells that did not endogenously secrete Chi3L1, but for which Chi3L1
secretion could be induced to various levels by OSM. Group 3 skin
cells behaved similarly to normal controls, as they did not endogenouslyTable 3
Clinical parameters and Chi3L1 secretion from cells of SSc patients obtained from either the fo
Patient characteristics
Patient ID Gender Age Disease duration (years) SSc sub-type
25 Female 70 17.5 Diffuse
27 Female 62 4.7 Limited
28 Female 46 7.1 Diffuse
30 Female 63 28.9 Limited
31 Male 53 6.3 Limited
33 Female 63 5.8 Limited
36 Female 45 5.6 Diffuse
37 Female 57 5.5 Diffuse
38 Male 43 4.9 Limited
21 Female 49 10.1 Diffuse
22 Female 59 12.3 Diffuse
23 Female 55 6.9 Limited
24 Male 70 10.8 Diffuse
26 Female 43 18.7 Limited
29 Female 56 5.5 Diffuse
32 Female 39 8.8 Diffuse
34 Female 56 9.7 Limited
35 Female 59 7.9 Diffuse
39 Female 62 1.3 Limited
40 Female 67 12.1 Limited
41 Female 63 2.6 Limited
Cells were isolated from skin biopsies obtained from the indicated sites and cultured in the abs
media. Chi3L1 secretion was induced by OSM in cells isolated from all forearm biopsies. + indic
OSM, but does not reﬂect absolute levels.secrete Chi3L1 and Chi3L1 secretionwas not induciblewith OSM. Of the
SSc skin cell lines studied, 22 (36%) belonged to Group 1, 19 (31%) to
Group 2, and 20 (33%) to Group 3. Absolute levels of endogenous
and/or inducible Chi3L1 varied considerably within each group (Fig. 3)
ranging from barely detectable to high levels.
3.3. Comparison of response patterns of peripheral and abdominal skin cells
From the data summarized in Tables 2 and 3 it can be seen that
Chi3L1 secretion was inducible by OSM in all 29 cell cultures prepared
from the peripheral skin (arm biopsies) of SSc patients. Endogenous
secretion was observed in 16 (55%) of these preparations. In contrast,rearm or the abdomen.
Chi3L1 secretion
Biopsy site Biopsy clinically involved Endogenous Induced by OSM
Arm No + +
Arm Yes + +
Arm No − +
Arm No − +
Arm Yes + +
Arm No − +
Arm Yes − +
Arm No + +
Arm No + +
Abdomen Yes − −
Abdomen No − −
Abdomen No − −
Abdomen No − −
Abdomen No − −
Abdomen No − −
Abdomen No − −
Abdomen No − −
Abdomen No − −
Abdomen No + +
Abdomen No − −
Abdomen No + +
ence or presence of OSM. Chi3L1 secretion was determined by western blotting of culture
ates detection of endogenous Chi3L1 or an increase over the endogenous level induced by
Table 4
Patient skin scores.
Patient ID Gender Age (years) mRSS Skin score (arm) Skin score (abdomen)
1 Female 53 2 0 0
2 Male 69 4 0 0
3 Female 58 33 4 2
4 Female 52 2 0 0
5 Female 55 9 0 0
6 Female 63 13 0 0
7 Female 60 1 0 0
8 Female 46 17 4 0
9 Female 78 10 0 0
10 Male 63 10 0 0
11 Female 49 1 0 0
12 Female 64 2 0 0
13 Female 66 4 0 0
14 Female 51 31 4 4
15 Female 70 3 0 0
16 Female 61 2 0 0
17 Female 69 2 0 0
18 Male 77 2 0 0
19 Female 46 0 0 0
20 Female 55 29 2 2
25 Female 70 10 2
27 Female 62 10 1
28 Female 46 10 0
30 Female 63 36 5
31 Male 53 7 0
33 Female 63 7 1
36 Female 45 9 0
37 Female 57 39 4
38 Male 43 6 0
21 Female 49 2 0
22 Female 59 2 0
23 Female 55 29 1
24 Male 70 2 0
26 Female 43 2 0
29 Female 56 30 0
32 Female 39 7 0
34 Female 56 29 1
35 Female 59 12 0
39 Female 62 4 0
40 Female 67 12 0
41 Female 63 11 0
Fig. 1. Comparison of Chi3L1 secretion by normal (A) and SSc (B) skin cells. Results are
shown for representative samples from 15 normal skin cells and 22 SSc skin cell lines.
Skin cells were grown in monolayer culture and stimulated for 48 h with cytokines or
growth factors (IL-1β, IL-6, IL-17, OSM, TGF-β and PDGF). Chi3L1 levels in culture media
were measured by SDS-PAGE and immunoblotting. Skin cell lines used in this experiment
were in passage 5. The left-hand lane of the gel shows the migration of molecular weight
markers, and the right-hand lane shows the migration of puriﬁed Chi3L1. Each medium
sample was spiked with equal amounts of biotinylated SBTI to monitor acetone precipita-
tion efﬁciency.
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rations; induction of Chi3L1 secretion by OSM was observed in 12
samples (38%), and 8 of these produced the protein endogenously,
while the remaining 20 samples behaved like cells from healthyTable 5
Chi3L1 secretion from skin cells obtained from healthy control individuals.
Control ID Gender Age Biopsy site Chi3L1 secretion
Basal Induced by OSM
1 Male 60 Arm − −
2 Female 58 Arm − −
Abdomen − −
3 Female 50 Arm − −
Abdomen − −
4 Female 47 Arm − −
5 Female 51 Arm − −
Abdomen − −
6 Female 57 Arm − −
7 Female 44 Arm − −
8 Female 50 Arm − −
Abdomen − −
9 Female 49 Arm − −
10 Female 61 Arm − −
Abdomen − −
Cells were isolated from skin biopsies obtained from healthy individuals and cultured in
the absence or presence of OSM. Culture media were analyzed for the presence of
Chi3L1 by western blotting. Paired biopsies were obtained from 5 individuals. No Chi3L1
was detectable in any of the 15 samples either in unstimulated cultures or following
exposure to OSM.individuals, i.e. no Chi3L1 production was detectable under any of the
experimental conditions. It should be noted that all cell lines where en-
dogenous secretion of Chi3L1 was observed responded to OSM,
independent of the biopsy site (arm or abdomen).
Matching biopsies taken from both the arm and abdomen were
available from 20 of the SSc patients used in this study, allowing com-
parison of the capacity to secrete Chi3L1 relative to the biopsy site in
individual patients (Table 2). In 6 patients, unstimulated cells from
both sites endogenously produced Chi3L1 and its secretion was in-
creased by OSM, and in a further 4 patients Chi3L1 production was
not detectable in unstimulated cells from both sites, but was induced
following addition of OSM. No Chi3L1 production either in the absenceFig. 2. Comparison of Chi3L1 secretion in response to OSM at different cell passages. One
representative sample of 3 SSc skin cell lines that endogenously secreted Chi3L1 and
were up-regulated upon stimulation byOSM is shown. Skin cells were grown inmonolay-
er culture with or without OSM stimulation for 48 h. Chi3L1 secretion into the culture
mediumwas measured by SDS-PAGE and immunoblotting. P7–P10: cell passage number;
C: unstimulated cells; O: OSM-induced cells. The left-hand lane of the gel shows the
migration of molecular weight markers, and the right-hand lane shows the migration of
puriﬁed Chi3L1. Biotinylated SBTI was added to each medium sample to monitor acetone
precipitation efﬁciency.
Fig. 3. Classiﬁcation of SSc skin cell phenotype based on endogenous and OSM-inducible
Chi3L1 secretion. Skin cells were grown in monolayer culture with or without OSM stim-
ulation for 48 h. Chi3L1 secretion into the culture medium was then measured by SDS-
PAGE and immunoblotting. Skin cell lines used in this experiment were in passage 5.
Eight representative samples of 61 cell preparations from 41 SSc patients are shown.
Group 1: SSc cells that endogenously secrete Chi3L1 and for which OSM stimulation
upregulates Chi3L1 secretion. Group 2: SSc cells that do not endogenously secrete
Chi3L1, but the protein is inducible by OSM. Group 3: SSc cells that do not endogenously
secrete Chi3L1 and its secretion is not inducible with OSM. The left-hand lane of each
gel shows the migration of molecular weight markers, and the right-hand lane shows
the migration of puriﬁed Chi3L1. Biotinylated SBTI was added to each medium sample
to monitor acetone precipitation efﬁciency.
Fig. 4.Comparison of Chi3L1 secretion by skin cells from arm and abdominal biopsies. Results fro
for 48 h with a variety of cytokines and growth factors (IL-1β, IL-6, OSM, TGF-β and PDGF). Sk
mediumwas measured by SDS-PAGE and immunoblotting. The left-hand lane of the gel shows
of puriﬁed Chi3L1. Biotinylated SBTIwas added to eachmedium sample tomonitor acetone pre
7Y.Y. Ho et al. / BBA Clinical 1 (2014) 2–11of stimulation or following addition of OSMwas observed in abdominal
cell preparations from 10 patients, while peripheral cells from these in-
dividuals always produced Chi3L1. This is illustrated in Fig. 4, which
shows the response of cells from arm and abdominal skin biopsies
taken from two representative SSc patients at the same time and
analyzed at the same cell passage level. Skin cells from both the arm
and abdomen of patient 14 (Fig. 4A) did not endogenously secrete
Chi3L1, but Chi3L1 secretion was inducible by IL-1 and OSM in the
cells fromboth sites. Skin cells from the armof patient 8 (Fig. 4B) endog-
enously secreted Chi3L1 and Chi3L1 secretion was upregulated by IL-1
andOSM, but abdominal skin cells from the samepatient did not endog-
enously secrete Chi3L1 nor was the protein inducible by IL-1 or OSM.
Thus while peripheral skin cells from SSc patients always contain a
cell population which is primed to allow upregulation of Chi3L1 by in-
ﬂammatory cytokines, this is not always the case for abdominal skin
cells.3.4. Variation in Chi3L1 secretion pattern with disease duration
Chi3L1 secretion patterns did not appear to correlate with any of the
typical features associated with SSc. Endogenous secretion and/or in-
ducibility by OSMwas observed in patients diagnosedwith either limit-
ed or diffuse SSc, and in biopsies taken from both clinically involved
(ﬁbrotic lesions) and non-involved sites (Tables 2 and 3). Also, Chi3L1
secretion by skin cells of SSc patientswasnot correlatedwith skin scores
(Table 4) or with clinical outcomes, such as digital ulcers, interstitial
lung disease and pulmonary hypertension, disease activity and disease
severity (data not shown). However, it was noted that patients
exhibiting endogenous secretion of Chi3L1 in cells from both biopsym two SSc patients are shown. Skin cells were grown inmonolayer culture and stimulated
in cell lines used in this experiment were in passage 5. Chi3L1 secretion into the culture
the migration of molecular weight markers, and the right-hand lane shows the migration
cipitation efﬁciency. Phenotype details of patients 14 (A) and 8 (B) are presented in Table 2.
8 Y.Y. Ho et al. / BBA Clinical 1 (2014) 2–11sites were in the early phase of disease, with a disease duration of
b2.5 years (Table 2). The shortest disease duration for patients
exhibiting other secretion patterns was 2.9 years with a median of
12.6 years.Meandisease durationwas signiﬁcantly reduced for patients
showing Chi3L1 expression in cells from both sites (P = 0.0005) and
at only the forearm site (P = 0.026). This suggests that the capacity
for endogenous production of Chi3L1 may be related to pathological
processes active at early disease stages.Fig. 5. Identiﬁcation of cells in SSc dermal cell culture that endogenously express Chi3L1. Cells
ﬂuorescencemicroscopy. One representative of 6 culture lines is shown for cells in passage 6. (A
the cell population. (B) Unstimulated Chi3L1-expressing cells do not co-localize withmyoﬁbrob
not affect myoﬁbroblasts. (D) TGF-β depletes the expression of Chi3L1 but increases the abund3.5. Characterization of Chi3L1-expressing cells
Six dermal cell lines from SSc patients previously shown to endoge-
nously produce Chi3L1 in cells derived from both arm and abdomen
were analyzed in this study. A heterogeneous cell population was
observed, with Chi3L1 endogenous expression only being detected in
5.4–10.7% of the cells, which were often seen in clusters (Fig. 5A).
Thus Chi3L1 production is not a feature of the general ﬁbroblastwere identiﬁed for Chi3L1 and αSMA, a marker of mature myoﬁbroblasts, using immuno-
) The Chi3L1 expressing cells are present in clusters and represent approximately 5–10% of
lasts. (C) OSM stimulation nearly doubles the number of Chi3L1-expressing cells but does
ance of myoﬁbroblasts. Bars represent 100 μm.
9Y.Y. Ho et al. / BBA Clinical 1 (2014) 2–11population. Some myoﬁbroblasts with characteristic actin stress ﬁbers
are evident in the cell preparations, but they do not co-localize with
the Chi3L1 expressing cells (Fig. 5B). Upon OSM stimulation, the num-
ber of Chi3L1 expressing cells nearly doubled to 10.2–19.6% of the
total cell population, with the cells still being unrelated to the
myoﬁbroblasts (Fig. 5C). In contrast, upon TGF-β stimulation, when
many of the SSc skin cells are transformed to αSMA-expressing
myoﬁbroblasts, Chi3L1 expression is absent (Fig. 5D). This suggests
that Chi3L1 expression in SSc dermal cells is up-regulated by pro-
inﬂammatory stimulation but down-regulated by pro-ﬁbrotic stimula-
tion, and that cells other than typical ﬁbroblasts and myoﬁbroblasts
are responsible for its production.
In recent years, it has been demonstrated that the dermis of SSc
patients may contain a multiplicity of cell types other than ﬁbroblasts
andmyoﬁbroblasts. These cell types include bonemarrow-derivedmes-
enchymal stem cells [41], pericytes [42], endothelial progenitor cells
[43], and circulating progenitor cells, such as ﬁbrocytes and monocytes
[41, 44, 45]. The SSc cell lineswere therefore analyzed for the expression
of the markers speciﬁc for these other cell types to determine whether
they could be the source of Chi3L1 expression. Immunoﬂuorescence
dual localization revealed that the SSc dermal cells that endogenously
expressed Chi3L1 also co-expressed the progenitor/stem cell marker,
nestin (Fig. 6A). These cells also expressed STRO-1, CD73, TIE2, LSP-1
and NG2, but not CD34 and CD45 (results not shown). Cell counting
showed that the nestin-positive cells constituted 4.9–9.9% of the total
cell population. Dermal cells from healthy controls showed no expres-
sion of the aforementioned cell markers (results not shown). ThusFig. 6. Co-localization of Chi3L1-expressing cells and nestin byﬂuorescencemicroscopy. (A) SSc
approximately 5–10% of the cells showed positive staining. One representative of 6 culture lin
endogenously expressed Chi3L1, the number of Chi3L1-expressing cells doubled while the nu
not express nestin are in close proximity to those that express both nestin and Chi3L1. One r
that do not endogenously express Chi3L1 also do not express nestin. Approximately 4–8% of t
of 3 culture lines is shown for cells in passage 6. Bar represents 100 μm.endogenous Chi3L1 production in the SSc dermis appears to originate
from cells with stem cell-like characteristics. It is, however, not clear if
these cells represent a single cell type or are of multiple cell lineages.
While Chi3L1 expressing cells nearly doubled upon OSM stimula-
tion, the number of cells expressing nestin (or STRO-1, CD73, TIE2,
LSP-1 and NG2) remained relatively constant at 5.2–10.1% of the total
cell population from patients with endogenous Chi3L1 expression. In-
terestingly, upon OSM stimulation, some of the cells that expressed
Chi3L1most exuberantly did not express the stem cell markers. Howev-
er, these cells are observed to be closely associated with those that
express both Chi3L1 and nestin (Fig. 6B).
In addition, ﬁve SSc dermal cell lines that did not endogenously
express Chi3L1 but in which the protein was inducible by OSM were
also studied. Immunoﬂuorescence for Chi3L1 conﬁrmed that there
was no endogenous Chi3L1 expression, and indicated that upon OSM
stimulation Chi3L1 expression was induced in approximately 4.1–7.9%
of cells. Unlike cells that endogenously express Chi3L1, this group of
cells were not stained for nestin (Fig. 6C) or any of the other progenitor/
stem cell markers tested.
4. Discussion
In this study we investigated the capacity of skin cells from SSc pa-
tients and from healthy individuals to secrete Chi3L1 and we assessed
the regulation of this process by growth factors and cytokines shown
to be associated with the pathology of SSc. The results demonstrate
that Chi3L1 is not secreted endogenously by normal skin cells nor is itdermal cell lines that endogenously express Chi3L1 also express nestin.With bothmarkers
es is shown for cells in passage 6. (B) Upon OSM stimulation of SSc dermal cell lines that
mber of cells expressing nestin remained unchanged. The Chi3L1 expressing cells that do
epresentative of 6 culture lines is shown for cells in passage 6. (C) SSc dermal cell lines
hese cells can be induced to express Chi3L1 upon stimulation of OSM. One representative
10 Y.Y. Ho et al. / BBA Clinical 1 (2014) 2–11induced by inﬂammatory cytokines such as OSMand IL-1. In contrast, all
cell preparations obtained from peripheral skin biopsies of SSc patients
responded to OSM with increased Chi3L1 secretion into the culture
medium, and endogenous production was clearly detectable in a
proportion of the cell preparations. This property was independent
of clinical status, but cells from both arm and abdomen of subjects
with early disease were more likely to demonstrate endogenous
secretion of Chi3L1 than those with more advanced disease. The cells
responsible for endogenous production of Chi3L1 did not appear to be
typical ﬁbroblasts or myoﬁbroblasts, but consisted of about 5–10% of
the SSc skin cell population that had stem cell-like features. The in-
creased production of Chi3L1 in response to OSM, however, involved
additional cells. Thus the cells involved in ﬁbrosis and contracture
appear to be distinct from those responsible for Chi3L1 production.
The lack of Chi3L1 production by normal skin ﬁbroblasts in the
absence or presence of growth factors or cytokines is consistentwith lit-
erature reports [28, 39, 46, 47]. Thus the detection of Chi3L1 in culture
media from SSc skin cell preparations was unexpected, indicating the
presence of a cell population with an altered phenotype compared to
healthy skin. Identiﬁcation of Chi3L1 producing cells by immunoﬂuores-
cence microscopy suggested that a relatively small proportion of the
cells actually produced Chi3L1 even after exposure to OSM. The cells re-
sponsible for endogenous production of Chi3L1 expressed a variety of
progenitor/stem cell markers, namely nestin, STRO-1, CD73, TIE2, LSP-
1 and NG2. Nestin is a class VI intermediate ﬁlament protein reported
to be expressed in neural tube-associated neural stem cells [48], but is
also used as a general marker for progenitor cells, including
skin-derived progenitor cells [49] and endothelial progenitor cells [50].
STRO-1 and CD73 are cell surface proteins commonly used as markers
for bonemarrow-derivedmesenchymal stem cells [51]. TIE2 is an endo-
thelial tyrosine kinase receptor that has been proposed to be the earliest
mammalian endothelial cell lineage marker [52]. LSP-1 is a marker for
ﬁbrocytes — circulating bone marrow-derived mononuclear cells that
have the capacity to deposit extracellular matrix in wound healing and
numerousﬁbrotic disorders, including SSc [53]. NG2 is a cell surface pro-
teoglycan widely expressed in both vasculogenic and angiogenic
neovasculature, and is accepted as amarker for pericytes inmicrovessels
[54]. The cells that express Chi3L1 did not stain for CD34 and CD45 (re-
sults not shown), suggesting that the cells do not have hematopoietic
potential. At present, the origin of the cells co-expressing Chi3L1 and pro-
genitor/stem cell markers is not known, but bone marrow appears to be
the common source of such cells. It is also not clear if the ability of the pro-
genitor/stem cells to reactwith a diversity ofmarkers is a reﬂection of dif-
ferent transient stageswithin a single cell differentiation pathway or is an
indication of different subpopulations. It is interesting to note that a re-
cent study has shown that Chi3L1 expression is a property of both undif-
ferentiated and differentiated mesenchymal stem cells [55].
The present study showed that OSM stimulation of SSc dermal cell
cultures that endogenously express both Chi3L1 and progenitor/stem
cell markers nearly doubled the number of Chi3L1 expressing cells but
not cells that bear progenitor/stem cellmarkers. However, the induction
of Chi3L1 upregulation is observed to occur in cells in very close proxim-
ity to the cells that co-express Chi3L1 and progenitor/stem cell markers.
These OSM-responsive cells appear to be activated ﬁbroblasts since they
also co-express S100A4 (ﬁbroblast-speciﬁc protein, FSP-1) (results not
shown), and it is possible that they could represent the differentiated
product of the progenitor/stem cells. OSM was also observed to induce
expression of Chi3L1 in some SSc dermal cell cultures that did not
show endogenous Chi3L1 expression and contained no cells with pro-
genitor/stem cell markers. The cells that were induced by OSM to ex-
press Chi3L1 could also represent activated ﬁbroblasts as they also co-
express S100A4 (results not shown). As the patients without endoge-
nous Chi3L1 expression tend to have a longer disease duration it is pos-
sible that all progenitor/stem cells that were present earlier have now
differentiated. Unlike normal ﬁbroblasts, these cells are primed to re-
spond to inﬂammatory cytokines with increased Chi3L1 production.While peripheral skin cells from SSc patients always produced
Chi3L1 following OSM stimulation, abdominal cells behaved in a more
sporadic fashion. This is not unexpected, as peripheral skin is more
likely to be clinically involved in SSc than the abdomen. However, the
present ﬁndings suggest that even when the skin on the forearm ap-
pears clinically normal, a pathophysiologic process characterized by
the presence of cells capable of Chi3L1 secretion is ongoing. The ﬁnding
that inmatched samples endogenous Chi3L1 secretion tends to bemore
consistently upregulated in cells from both sites in SSc patients with a
short disease duration, suggests that with time the widespread patho-
logical process that is reﬂected by generalized endogenous Chi3L1 se-
cretion diminishes and is replaced by more focal pathology. If Chi3L1
secretion does indeed reﬂect an active process, there is no a priori rea-
son for a clear relationship between clinical skin thickening and
Chi3L1 secretion. It is possible that Chi3L1 production is not reﬂected
in clinically detectable skin thickening associated with ﬁbrosis because
it is either too early for this feature to present, or because turnover of
ECM is initially able to keep pace with the increased ECM production
associated with ﬁbrosis. It is also unclear whether Chi3L1 has any direct
effect on collagen production, though it may do so indirectly by stimu-
lation of ﬁbroblast proliferation [29].
The present study showed that endogenous secretion of Chi3L1 and/
or inducibility by OSM did not distinguish patients with limited or dif-
fuse SSc. Also, Chi3L1 secretion by SSc skin cells could not be related
to clinical features, such as skin score, digital ulcers, interstitial lung dis-
ease, pulmonary hypertension and disease activity. However, other
groups have reported that SSc patients with higher Chi3L1 serum levels
exhibited an elevated incidence of pulmonary ﬁbrosis, greater disease
severity and shorter survival time [23]. An enhanced Chi3L1 serum
level has also been reported to be associated with joint involvement in
SSc patients [22, 24]. However, the cellular source of serum Chi3L1 is
not known, but is likely to reﬂect variable levels of secretion from
many sources. As such, it is not possible to relate the level of serum
Chi3L1 to the level in any given tissue. Only direct analysis of speciﬁc
tissues, as performed in this study, will permit this issue to be resolved.
While the biological functions of Chi3L1 have not been determined
in SSc, the protein could be involved in modulating the inﬂammatory
response. Previous work has shown that Chi3L1 can modulate the re-
sponse of connective tissue cells to inﬂammatory cytokines by reducing
the response of human chondrocytes to IL-1 or TNF-α [32]. This sug-
gests that Chi3L1 is produced in response to pro-inﬂammatory stimula-
tion, but once it is secreted, it can exert a proﬁbrotic effect by reducing
the turnover of extracellular matrix components. Thus, the induction
and up-regulation of Chi3L1 by IL-1 and/or OSM in some SSc skin cells
could occur during inﬂammation, where it may limit tissue damage.Conﬂict of interest
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